Needham analyst Joshua Reilly raised the firm’s price target on Axon (AXON) to $870 from $820 and keeps a Buy rating on the shares. The company reported another strong quarter with a 420 bps beat on revenue vs. consensus estimates, including strength across both new and existing products, the analyst tells investors in a research note. A potentially significant needle mover could come in the second half as European countrywide deals for TASER, Bodycam and software products are gaining greater interest, the firm added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXON:
- Craig-Hallum upgrades Axon to Buy from Hold
- Axon price target raised to $840 from $820 at UBS
- Axon upgraded to Buy from Hold at Craig-Hallum
- Axon Enterprise’s Strong Growth Potential and Increased Price Target Amid Surpassing Revenue Expectations
- Axon Enterprise’s Strong Financial Performance and Strategic Growth Drive Buy Rating